SCHEMBL2160146

SCHEMBL2160146

Nc1nnc(-c2cnccn2)s1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 3/20 0.49
CYP1A2 P05177 1/20 0.49
HSD17B10 Q99714 4/20 0.48
HPGD P15428 2/20 0.48
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
TERT O14746 6/20 0.44
PIEZO1 Q92508 1/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PI4KA P42356 1/20 0.43
PIK3CG P48736 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214179 0.78 TERT (0.52) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL19336777 0.77 KDM4E (0.53) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL971837 0.77 KDM4E (0.49) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL3137543 0.74 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1CYP1A2HSD17B10
SCHEMBL15048585 0.74 KDM4E (0.54) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL8143194 0.73 KDM4E (0.74) KDM4ESMN1; SMN2ALDH1A1CYP1A2HSD17B10
SCHEMBL17225713 0.73 ALDH1A1 (0.49) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL17225689 0.73 ALDH1A1 (0.52) KDM4ESMN1; SMN2ALDH1A1CYP1A2HSD17B10
SCHEMBL15399054 0.73 TERT (0.48) KDM4EALDH1A1CYP1A2HSD17B10HPGD
SCHEMBL17835736 0.72 KDM4E (0.56) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP claimed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US claimed
CN-119751439-A ATF6 modulators and uses thereof 阿尔托斯实验室公司 2025-04-04 CN disclosed
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
CN-115087656-B ATF6 modulators and uses thereof 阿尔托斯实验室公司 2024-12-13 CN disclosed
EP-4436968-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2024-10-02 EP disclosed
CN-118201924-A Heterocyclic compounds and their use 万特斯治疗美国公司 2024-06-14 CN disclosed
WO-2023081441-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-05-11 WO disclosed
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ALTOS LABS, INC. 2023-01-26 US disclosed
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ALTOS LABS, INC. 2023-01-26 US disclosed
CN-115087656-A ATF6 modulators and uses thereof 普拉西斯生物技术有限责任公司 2022-09-20 CN disclosed
EP-4041728-A1 ATF6 MODULATORS AND USES THEREOF Praxis Biotech LLC (US) 2022-08-17 EP disclosed
WO-2021069721-A1 ATF6 MODULATORS AND USES THEREOF BLACK BELT TX LTD (GB) 2021-04-15 WO disclosed
WO-2021069721-A1 ATF6 MODULATORS AND USES THEREOF BLACK BELT TX LTD (GB) 2021-04-15 WO disclosed
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP disclosed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US disclosed
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 US disclosed
WO-2011089132-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CGAS, TDP1, CYP11B2 KDM4E 4732/4885SMN1; SMN2 1142/4885ALDH1A1 987/4885
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ATF4, XBP1, ATF1 KDM4E 4378/4885SMN1; SMN2 881/4885ALDH1A1 3911/4885
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES PDE3A, PDE2A, PDE10A KDM4E 2200/4885SMN1; SMN2 2475/4885ALDH1A1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.